A multi-center, single-arm, phase II study of pemigatinib combined with immune checkpoint inhibitor in FGFR1/2/3 alteration advanced solid tumor.

Authors: Tao Qin

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2692

Source: Full article

---

Abstract

TPS2692